DOCSLIB.ORG

Dimethyl Fumarate Decreases Neurofilament Light Chain in CSF

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dimethyl Fumarate Decreases Neurofilament Light Chain in CSF J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-321321 on 13 October 2019. Downloaded from Multiple sclerosis ORIGINAL RESEARCH Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients Tobias Sejbaek ,1,2,3,4,5 Helle Hvilsted Nielsen,1,2,5 Natasha Penner,6 Tatiana Plavina,6 Jason P Mendoza,6 Nellie Anne Martin,2 Maria Louise Elkjaer,1,2 Mads Henrik Ravnborg,1 Zsolt Illes 1,2,5 ► Additional material is ABSTRact disease modifying therapies (DMTs), such as natal- published online only. To view Objectives In a prospective phase IV trial of the izumab, fingolimod, cladribine, daclizumab and please visit the journal online first-line oral treatment dimethyl fumarate (DMF), we alemtuzumab resulted in significant reduction in (http:// dx. doi. org/ 10. 1136/ 8–13 jnnp- 2019- 321321). examined dynamics of neurofilament light N( FL) chain NFL in the CSF and blood. Switch from inject- in serum, plasma and cerebrospinal fluid (CSF) samples ables to fingolimod reduced NFL concentration in 1Neurology, Odense collected over 12 months from relapsing-remitting the plasma, and switch to rituximab decreased NFL Universitetshospital, Odense, multiple sclerosis (RRMS) patients. NFL changes were levels in the CSF.14 15 In patients treated with natali- Denmark 2Department of Clinical related to disease activity. zumab, such reduction in NFL in the CSF correlated 16 Research, University of Southern Methods We examined NFL levels by single-molecule with brain atrophy changes. Therefore, NFL has Denmark, Odense, Denmark array in 88 CSF, 348 plasma and 131 sera from been suggested as a supplementary biomarker in the 3 Neurology, Hospital of South treatment-naïve RRMS patients (n=52), healthy controls management of MS.17 West Jutland, Esbjerg, Denmark 4 Prospective studies that investigate changes of The Department of Regional (n=23) and a placebo group matched by age, sex and Health Research, University of NFL (n=52). Plasma/sera were collected at baseline, and NFL in the blood and CSF during treatment with Southern Denmark, Odense, 1, 3, 6 and 12 months after DMF. CSF samples were first-line DMTs are lacking. In this prospective Denmark open label phase IV study, we investigated dynamic 5 collected at baseline and 12 months after DMF. MS Alliance of Southern Results NFL concentration in CSF, plasma and serum changes of NFL concentration in parallel samples Denmark, Esbjerg, Denmark 6Value Based Medicine, correlated highly (p<0.0001 for all), but plasma levels of serum, plasma and CSF taken from newly diag- Biogen Idec Inc, Cambridge, were only 76.9% of paired serum concentration. nosed treatment-naïve relapsing-remitting multiple Massachusetts, USA After 12 months of DMF treatment, NFL concentration sclerosis (RRMS) patients after treatment with decreased by 73%, 69% and 55% in the CSF, serum and dimethyl fumarate (DMF). We also compared NFL Correspondence to plasma (p<0.0001, respectively). Significant reduction levels in MS patients before and after DMF treat- Dr Tobias Sejbaek, Neurology, in blood was observed after 6 and 12 months treatment ment to healthy controls and placebo patients from Hospital of South West Jutland, Esbjerg 5000, Denmark; Tobias. compared with baseline (p<0.01 and p<0.0001, the randomised phase III trial: Pegylated interferon Sejbaek. Mathiesen@ rsyd. dk respectively) and to placebo (p<0.0001). Patients with β−1a for relapsing-remitting multiple sclerosis NFL above the 807.5 pg/mL cut-off in CSF had 5.0-times (ADVANCE).18 http://jnnp.bmj.com/ Received 30 May 2019 relative risk of disease activity (p<0.001). Revised 24 September 2019 Accepted 28 September 2019 Conclusions This study provides Class II evidence that METHODS first-line DMF reduces NFL in both blood and CSF after Study design 6 months and normalises CSF levels in 73% of patients. TREMEND (Tecfidera in Relapsing-Remitting High NFL concentration in CSF after a year reflected Multiple Sclerosis: Endothelial Dysfunction) was disease activity. NFL levels were higher in serum than in a prospective open label phase IV trial which plasma, which should be considered when NFL is used as enrolled newly diagnosed MS patients with RRMS on October 1, 2021 by guest. Protected copyright. a biomarker. from March 2014 till August 2016 (EudraCT 2014- ► http:// dx. doi. org/ 10. 1136/ 000254-11) (see online supplementary figure 1). jnnp- 2019- 321615 TREMEND was a study designed to identify poten- tial biomarkers in DMF-treated MS patients. The INTRODUCTION primary and secondary objectives were the change © Author(s) (or their Levels of the cytoskeleton protein neurofilament in the levels of biomarkers from baseline by month employer(s)) 2019. Re-use light (NFL) are increased in the cerebrospinal fluid 12 and 24 in subjects with RRMS receiving DMF. permitted under CC BY-NC. No (CSF) and blood in diseases associated with axonal Analysing NFL was one of the biomarker endpoints, commercial re-use. See rights damage.1 If measured by sensitive methods, blood and part of the original protocol. and permissions. Published 2–4 by BMJ. and CSF concentrations of NFL correlate. We included untreated (naïve) newly diag- Studies have shown that in the blood and CSF of nosed MS patients with RRMS according to the To cite: Sejbaek T, Nielsen patients with multiple sclerosis (MS), NFL concen- McDonald 2010 criteria (table 1).19 All patients HH, Penner N, et al. J Neurol tration is elevated at the time of diagnosis compared had oligoclonal bands (OCBs) in the CSF (n=52). Neurosurg Psychiatry Epub ahead of print: [please with healthy controls (HC) and is associated with The reason for including only patients with positive 5 include Day Month Year]. disease severity and prognosis. NFL levels are also OCBs was to ensure that participants had active doi:10.1136/jnnp-2019- increased during relapse and when new lesions are disease since absence of OCBs has been described 321321 detected by MRI.6 7 Treatment with highly effective a marker of low disease activity20 and support the Sejbaek T, et al. J Neurol Neurosurg Psychiatry 2019;0:1–7. doi:10.1136/jnnp-2019-321321 1 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-321321 on 13 October 2019. Downloaded from Multiple sclerosis Standard protocol approvals, registrations, patient consents Table 1 Demographics of study participants and baseline NFL and monitoring MS patients MS patients All patients and healthy controls gave written and oral consent. TREMEND ADVANCE The study was monitored according to the national laws by the DMF placebo Healthy controls (±SD) (±SD) (±SD) P value unit for good clinical practice at the hospital. Age (years) 34.1 (±8.7) 33.5 (±6.5) 38.2 (±11.2) ns Female/male 86.6% 90% 89.2% ns Data protection (%) This study was approved by the Danish Data Protection Agency Baseline CSF 2368 (±1947) N/A 416.8 (±191.2) P<0.0001 (journal no. 17/12684). NFL (pg/mL) Baseline 16.4 (±14.4) 17.5 (±14.0) 7.3 (±3.0) P<0.0001 Data availability plasma NFL Anonymised data will be shared on request from any qualified TREMEND (Tecfidera in Relapsing-Remitting Multiple Sclerosis: Endothelial investigator under approval from the Danish Data Protection Dysfunction) (n=52) and ADVANCE (Pegylated interferon β−1a for relapsing- remitting multiple sclerosis) (n=48)18; mean±SD is shown. P values represent Agency. difference between healthy controls (n=23) versus patients in the ADVANCE and TREMEND trial, respectively. There was no significant difference between the Statistical analyses ADVANCE and TREMEND trial. We described baseline characteristics with means and SDs for CSF, cerebrospinal fluid; DMF, dimethyl fumarate; MS, multiple sclerosis; N/A, not available; NFL, neurofilament light; ns, not significant. continuous variables and percentages for binary variables. Linear fit regression was performed using Spearman linear fit regression to calculate coefficients and linearity between NFL in CSF, plasma and serum. Data was checked for normality using inclusion of patients with MS even after a single clinical event.21 D'Agostino & Pearson normality test. Patients were recruited from two MS clinics of the MS Alli- Receiver operating characteristic (ROC) analysis was ance of Southern Denmark (Odense University Hospital and performed to identify cut-offs of NFL concentration in blood Hospital of South West Jutland), but the clinical examination and CSF that differentiate healthy controls and MS patients, and and sample preparation were performed by the same physician define their specificity and sensitivity. (TS) following identical protocols. We collected plasma and We used ordinary one-way analysis of variance and Holm-Si- sera at baseline, and 1, 3, 6 and 12 months after DMF treat- 22 dak’s multiple comparisons test in normal distributed data. In ment. Expanded Disability Status Scale (EDSS) scoring was the absence of Gaussian distribution, non-parametric analysis performed at the same time points and when clinical relapse was was performed with Kruskal-Wallis test and Dunn’s multiple suspected. CSF was collected at baseline (n=30) and optionally comparisons. 12 months after treatment (n=35). Altogether, we examined To analyse relative risk between high (above cut-off) and low 65 CSF samples, 108 serum samples and 230 plasma samples. (below cut-off) NFL levels in CSF and blood, we used Fish- Patients had brain MRI at baseline, 3 to 6 months after initia- er's exact test. Statistical analysis and data management were tion of DMF (re-baseline) and after 12 months table 1. Patients performed using GraphPad Prism 7. with relapses and/or new or enlarging T2-weighted lesions on MRI were defined as patients with disease activity (national guidelines).23 RESULTS We also collected CSF, plasma and serum from an age-matched NFL levels correlate in body fluids and are the lowest in http://jnnp.bmj.com/ and sex-matched healthy control cohort (n=23): patients plasma without neurological disease and neurological signs, and with To examine NFL in body fluids obtained from MS and HC, normal MRI and CSF results (table 1).
Load more

Recommended publications
  • Dimethyl Fumarate Or Any of the Excipients of TECFIDERA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION ___________________ CONTRAINDICATIONS ___________________ These highlights do not include all the information needed to use Known hypersensitivity to dimethyl fumarate or any of the excipients of TECFIDERA safely and effectively. See full prescribing information for TECFIDERA. (4) TECFIDERA. _______________ _______________ WARNINGS AND PRECAUTIONS TECFIDERA® (dimethyl fumarate) delayed-release capsules, for oral use • Anaphylaxis and angioedema: Discontinue and do not restart TECFIDERA Initial U.S. Approval: 2013 if these occur. (5.1) • Progressive multifocal leukoencephalopathy (PML): Withhold _________________ RECENT MAJOR CHANGES _________________ TECFIDERA at the first sign or symptom suggestive of PML. (5.2) Dosage and Administration, Blood Test Prior to • Lymphopenia: Obtain a CBC including lymphocyte count before initiating TECFIDERA, after 6 months, and every 6 to 12 months thereafter. Initiation of Therapy (2.2) 1/2017 9 Warnings and Precautions, PML (5.2) 2/2016 Consider interruption of TECFIDERA if lymphocyte counts <0.5 x 10 /L Warnings and Precautions, Liver Injury (5.4) 1/2017 persist for more than six months. (5.3) • Liver injury: Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels before initiating TECFIDERA and during treatment, __________________ INDICATIONS AND USAGE _________________ as clinically indicated. Discontinue TECFIDERA if clinically significant TECFIDERA is indicated for the treatment of patients with relapsing forms of liver injury induced by TECFIDERA is suspected. (5.4) multiple sclerosis (1) _______________ DOSAGE AND ADMINISTRATION ______________ ___________________ ADVERSE REACTIONS ___________________ • Starting dose: 120 mg twice a day, orally, for 7 days (2.1) Most common adverse reactions (incidence ≥10% and ≥2% placebo) were • Maintenance dose after 7 days: 240 mg twice a day, orally (2.1) flushing, abdominal pain, diarrhea, and nausea.
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]
  • Hpra Drug Safety 66Th Newsletter Edition
    FEBRUARY 2015 HPRA DRUG SAFETY 66TH NEWSLETTER EDITION 3 Mycophenolate mofetil (CellCept) and 4 Direct Healthcare Professional In this Edition Mycophenolic acid (Myfortic) - New warnings Communications published on about the risks of hypogammaglobulinaemia the HPRA website since the last 1 Eligard (leuprorelin acetate depot injection) and bronchiectasis Drug Safety Newsletter - Risk of lack of efficacy due to incorrect reconstitution and administration process 4 Tecfidera (dimethyl fumarate) - Progressive Multifocal Leukoencephalopathy (PML) has 2 Beta interferons – Risk of thrombotic occurred in a patient with severe microangiopathy and nephrotic syndrome and prolonged lymphopenia Eligard (leuprorelin acetate depot injection) - Risk of lack of efficacy due to incorrect reconstitution and administration process Following identification of a signal and safe treatment of patients with It is available in six-monthly (45mg), of administration errors with Eligard prostate cancer. Lack of efficacy may three-monthly (22.5mg) and one- and concerns that such errors may occur due to incorrect reconstitution monthly (7.5mg) formulations. In impact on clinical efficacy, this issue of Eligard. the majority of patients, androgen was reviewed at EU level by the deprivation therapy (ADT) with Eligard Eligard is indicated for the treatment Pharmacovigilance Risk Assessment results in testosterone levels below the of hormone dependent advanced Committee (PRAC). A cumulative standard castration threshold (<50ng/ prostate cancer and for the treatment review of reported global cases dL; <1.7 nmol/L); and in most cases, of high risk localised and locally identified errors related to storage, patients reach testosterone levels advanced hormone dependent preparation and reconstitution of below <20ng/dL. prostate cancer in combination Eligard.
    [Show full text]
  • Dimethyl Fumarate and Progressive Multifocal Leucoencephalopathy (PML)
    Dimethyl fumarate and progressive multifocal leucoencephalopathy (PML) Introduction Dimethyl fumarate Psorinovo® is not registered through the Medicines Evaluation Board (MEB). It is a compounded drug made by GMP compounding pharmacy Mierlo Hout in the Netherlands, and used for the indication psoriasis [1]. Psorinovo® has been compounded by pharmacy Mierlo Hout for 28 years. According to Dutch law Mierlo Hout pharmacy is regarded as a supplying-pharmacy. ® Dimethyl fumarate, registered as Tecfidera , was granted marketing authorization in the Netherlands on 30 January 2014 and is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis [2]. Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system caused by reactivation of the polyomavirus JC (JC virus). Asymptomatic primary infection with the JC virus occurs in childhood, antibodies can be found in 86% of adults. PML occurs almost exclusively in immunosuppressed individuals. There were only isolated cases reported of PML in patients without apparent immunosuppression. However, there are reports of PML affecting patients who have conditions associated with minimal or occult immunosuppression, such as hepatic cirrhosis and renal failure [3]. PML has also been reported in patients treated with drugs such as belatacept, brentuximab, efalizumab, fludarabine, glucocorticoids, infliximab, mycophenolate, rituximab, ruxolitinib and natalizumab. In some cases, these drugs were used in combination with other immunosuppressive medications (eg, cyclophosphamide, leflunomide, methotrexate). Many of the patients had an underlying hematologic malignancy or collagen vascular disease [3]. There is no specific treatment for PML. The main approach is restoring the host adaptive immune response, a strategy that appears to prolong survival.
    [Show full text]
  • Patent No.: US 8952006 B2
    USOO8952006B2 (12) United States Patent (10) Patent No.: US 8,952,006 B2 Cundy et al. (45) Date of Patent: *Feb. 10, 2015 (54) MORPHOLINOALKYL FUMARATE FOREIGN PATENT DOCUMENTS COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE W. wo.5: 886 WO WO O2/O55063 T 2002 (71) Applicant: XenoPort, Inc., Santa Clara, CA (US) WO WO O2/O55066 T 2002 WO WOO3,087.174 10, 2003 (72) Inventors: Kenneth C. Cundy, Redwood City, CA WO WO 2005/023241 3, 2005 WO WO 2005/027899 3, 2005 (US); Suresh K. Manthati, Sunnyvale, WO WO 2006/037342 4/2006 CA (US); David J. Wustrow, Los Gatos, WO WO 2006/122652 11, 2006 CA (US) WO WO 2007/042034 4/2007 WO 2010/022177 A2 2, 2010 (73) Assignee: XenoPort, Inc., Santa Clara, CA (US) WO 2014/0964.25 A2 6, 2014 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 2050 2057.* spent is Subject to a terminal dis- Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 1992 1996.* (21) Appl. No.: 13/761,864 Ey's statisfy it to (22) Filed: Feb. 7, 2013 com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index. e f 9 html>. (65) Prior Publication Data Atreya et al., NF-kB in inflammatory bowel disease, J Intern Med (2008), 263(6): 591-6. US 2013/02O3753 A1 Aug. 8, 2013 Bardgett et al., NMDA receptor blockade and hippocampal neuronal loss impair fear conditioning and position habit reversal in C57B1/6 mice, Brain Res Bull (2003), 60: 131-142.
    [Show full text]
  • The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
    pharmaceuticals Article The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis Roberto De Masi 1,2 , Stefania Orlando 1,* and Antonella De Donno 3 1 Laboratory of Neuroproteomics, Multiple Sclerosis Centre, “F. Ferrari” Hospital, 73042 Casarano, Lecce, Italy; dmsrrt@gmail.com 2 Complex Operative Unit of Neurology, “F. Ferrari” Hospital, 73042 Casarano, Lecce, Italy 3 Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, University of the Salento, 73100 Lecce, Italy; antonella.dedonno@unisalento.it * Correspondence: stefania.orlando@unisalento.it; Tel.: +39-0833-508-412 Abstract: We investigated the comparative age-related efficacy of dimethyl fumarate (DMF) and natalizumab (NTZ) in clinical practice on multiple sclerosis (MS). Research in this area is lacking in the previous literature. In a three-year retrospective and clinical–paraclinical study, we compared 173 DMF patients and 94 NTZ patients with a similar average age (40 years) and disease duration (DD) (10 years). Expanded Disability Status Scale (EDSS) scores were higher in the NTZ group than in the DMF group at 3.5 vs. 2.5, respectively (p = 0.001). However, in both groups, age values correlated with DD (r = 0.42; p < 0.001), EDSS (r = 0.52; p < 0.001) and age at onset (r = 0.18; p < 0.001). Furthermore, age-adjusted Kaplan–Meier curves showed that NTZ-treated subjects maintained a 1.0–3.0 EDSS status score (p = 0.003) more frequently and a 3.5–7.0 score (p = 0.022) significantly less frequently compared with DMF-treated subjects.
    [Show full text]
  • CVS Specialty® Pharmacy Distribution Drug List Providing One of the Broadest Offerings of Specialty Pharmaceuticals in the Industry
    July 2021 Updated Quarterly CVS Specialty® Pharmacy Distribution Drug List Providing one of the broadest offerings of specialty pharmaceuticals in the industry The CVS Specialty Pharmacy Distribution Drug List is a guide of medications available and distributed through CVS Specialty. Our goal is to help make your life better. With more than 40 years of experience, CVS Specialty provides quality care and service. Our network of pharmacies includes certifications and accreditations from the Joint Commission, Utilization Review Accreditation Commission (URAC), the National Association of Boards of Pharmacy (NABP) and the Accreditation Commission for Health Care (ACHC). These nationally recognized symbols reflect an organization’s commitment to meet highest standards of quality, compliance and safety. This list is updated quarterly. Below brand-name products are in CAPS, and generic products are shown in lowercase italics. Prospective Patients: Ready to get started? Enroll to get your medications from CVS Specialty. Health Care Providers: Visit the CVS Specialty website to download enrollment forms or call 1-800-237-2767 (TTY: 711). Therapy Class Brand Name Generic Name Acromegaly BYNFEZIA PEN octreotide acetate (SANDOSTATIN) SANDOSTATIN SANDOSTATIN LAR SOMATULINE DEPOT SOMAVERT Alcohol/Opioid Dependency PROBUPHINE IMPLANT KIT SUBLOCADE VIVITROL Allergen Immunotherapy ORALAIR PALFORZIA Alpha-1 Antitrypsin Deficiency ARALAST NP GLASSIA ZEMAIRA Amyloidosis ONPATTRO VYNDAMAX VYNDAQEL Anemia ARANESP EPOGEN PROCRIT REBLOZYL RETACRIT Asthma CINQAIR DUPIXENT FASENRA NUCALA XOLAIR Atopic Dermatitis DUPIXENT Botulinum Toxins DYSPORT MYOBLOC XEOMIN Cardiac Disorders ARCALYST dofetilide (TIKOSYN) TIKOSYN Specialty and non-specialty products distributed by CVS Specialty, as well as products covered by a member’s prescription or medical benefit plan, may change from time to time.
    [Show full text]
  • Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: a Comprehensive Review of Disease, Drug Efficacy and Side Effects
    Review Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects Grace Lassiter 1,*, Carlie Melancon 2, Tyler Rooney 2 , Anne-Marie Murat 2, Jessica S. Kaye 3, Adam M. Kaye 3 , Rachel J. Kaye 4, Elyse M. Cornett 5, Alan D. Kaye 5, Rutvij J. Shah 5,6, Omar Viswanath 5,7,8,9 and Ivan Urits 5,10 1 School of Medicine, Georgetown University, Washington, DC 20007, USA 2 School of Medicine, Louisiana State University Shreveport, Shreveport, LA 71103, USA; cmela8@lsuhsc.edu (C.M.); troone@lsuhsc.edu (T.R.); amurat@lsuhsc.edu (A.-M.M.) 3 Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA; j_kaye1@u.pacific.edu (J.S.K.); akaye@pacific.edu (A.M.K.) 4 School of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA; rachelkaye17@hotmail.com 5 Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA; ecorne@lsuhsc.edu (E.M.C.); akaye@lsuhsc.edu (A.D.K.); rshah2@lsuhsc.edu (R.J.S.); viswanoy@gmail.com (O.V.); ivanurits@gmail.com (I.U.) 6 Department of Neurology, Louisiana State University Shreveport, Shreveport, LA 71103, USA 7 College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85724, USA 8 Department of Anesthesiology, School of Medicine, Creighton University, Omaha, NE 68124, USA 9 Valley Anesthesiology and Pain Consultants—Envision Physician Services, Phoenix, AZ 85004, USA 10 Southcoast Health, Southcoast Physicians Group Pain Medicine, Wareham, MA 02571, USA * Correspondence: gml54@georgetown.edu Received: 23 October 2020; Accepted: 1 December 2020; Published: 3 December 2020 Abstract: Multiple sclerosis (MS) is a prevalent and debilitating neurologic condition characterized by widespread neurodegeneration and the formation of focal demyelinating plaques in the central nervous system.
    [Show full text]
  • Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
    Review Safety of Newer Disease Modifying Therapies in Multiple Sclerosis Georges Jalkh 1,2 , Rachelle Abi Nahed 1,2, Gabrielle Macaron 1,2,3 and Mary Rensel 3,* 1 Department of Neurology, Faculty of Medicine, Université Saint Joseph, Beirut B.P. 11-5076, Lebanon; georges.jalkh@net.usj.edu.lb (G.J.); rachelle.abinahed@net.usj.edu.lb (R.A.N.); gabrielle.macaron@hdf.usj.edu.lb (G.M.) 2 Department of Neurology, Hotel-Dieu de France Hospital, Beirut 16-6830, Lebanon 3 Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA * Correspondence: renselm@ccf.org; Tel.: +1-216-312-4219 Abstract: In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly. Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions are increasingly used early in the disease course. These newer DMTs include oral therapies (terifluno- mide, dimethyl fumarate, fingolimod, siponimod, ozanimod, and cladribine) and infusion therapies (natalizumab, alemtuzumab, and ocrelizumab), and are associated with better control of disease ac- tivity and long-term outcomes in patients with MS compared to older injectable therapies (interferon beta and glatiramer acetate). However, they are associated with safety concerns and subsequent monitoring requirements. Adverse events are initially observed in phase 2 and 3 clinical trials, and further long-term data are collected in phase 3 extension studies, case series, and post-marketing reports, which highlight the need to periodically re-evaluate and adjust monitoring strategies to optimize treatment safety in an individualized approach. Keywords: multiple sclerosis; disease modifying therapies; safety; long-term outcomes Citation: Jalkh, G.; Abi Nahed, R.; 1.
    [Show full text]
  • Dimethyl Fumarate (Tecfidera)
    Dimethyl fumarate (Tecfidera) This factsheet is about dimethyl fumarate, a MRI scans that MS is active. These signs include disease modifying therapy (DMT) for relapsing new ‘lesions’ (areas of damage) in your brain. multiple sclerosis (MS). At the end of this So you can take dimethyl factsheet you’ll find out where you can get more information on this drug, other drugs for fumarate if you have: MS and the benefits of early treatment. In Scotland, Wales and Northern Ireland: • relapsing MS and you’ve had a recent relapse This factsheet doesn’t cover everything about and/or MRI scans show new signs that your this drug and shouldn’t be used in place of MS is active (you have new ‘lesions’) advice from your MS specialist team. For more information speak to them and read the In England you can have this drug if: online information from the drug’s makers (see • you’ve had two relapses in the last two years the section More information and support). Whether you’ll be offered this drug depends on if you qualify for it based on guidelines used by your neurologist. These come from What is dimethyl the Association of British Neurologists (ABN) and NICE. In England there are rules from NHS fumarate? England about who can have the different DMTs In 2012 a trial showed that a drug called BG-12 and when. Scotland, Wales and Northern Ireland used for psoriasis, a skin problem, also worked also have their own guidelines for many DMTs. against MS. If you can have a drug also depends on whether In 2013 it was given the new name of dimethyl the NHS where you live will pay for it.
    [Show full text]
  • Tecfidera (Dimethyl Fumarate)
    <Date> Tecfidera® (dimethyl fumarate): Updated recommendations in the light of cases of progressive multifocal leukoencephalopathy (PML) in the setting of mild lymphopenia Dear Healthcare Professional, In agreement with the European Medicines Agency (EMA) and the [National Competent Authority] Biogen Netherlands B.V. would like to inform you of important updated information to help minimise the risk of progressive multifocal leukoencephalopathy (PML) in patients treated with Tecfidera. Summary • Cases of progressive multifocal leukoencephalopathy (PML) in the setting of mild lymphopenia (lymphocyte count ≥ 0.8 ×109/L and below the lower limit of normal) have been reported in patients treated with Tecfidera; previously, PML had been confirmed only in the setting of moderate to severe lymphopenia. • Tecfidera is contraindicated in patients with suspected or confirmed PML. • Tecfidera should not be initiated in patients with severe lymphopenia (lymphocyte counts < 0.5 ×109/L). • If the lymphocyte count is below the normal range, a thorough assessment of possible causes should be completed before initiating treatment with Tecfidera. • Tecfidera should be discontinued in patients with severe lymphopenia (lymphocyte counts < 0.5 ×109/L) persisting for more than 6 months. • If a patient develops PML, Tecfidera must be permanently discontinued. • Advise patients to inform their partner or caregivers about their treatment and symptoms suggestive of PML, since they may notice symptoms of which the patient is not aware. Background on the safety concern Tecfidera is authorised in the European Union for the treatment of adults with relapsing- remitting multiple sclerosis. Tecfidera may cause lymphopenia: in clinical trials lymphocyte counts decreased by approximately 30% of baseline value during treatment.
    [Show full text]
  • Zāļu Patēriņa Statistika 2018
    fa ZĀĻU PATĒRIŅA STATISTIKA STATISTICS ON MEDICINES CONSUMPTION 2018 ZĀĻU VALSTS AĢENTŪRA STATE AGENCY OF MEDICINES 2019 Autors/ Author: Zāļu valsts aģentūra Sagatavoja/ Prepared by: A. Seilis, E. Gailīte Izdevējs/ Publisher: Zāļu valsts aģentūra/ State Agency of Medicines© 2019 Izmantojot šajā grāmatā publicētos datus, jānorāda datu avots When using or quoting the data included in this issue, please indicate the source SATURS Ievads .................................................................................................................................................................................................. 6 Metode ............................................................................................................................................................................................... 7 Rezultāti .............................................................................................................................................................................................. 9 1. Iedzīvotāju skaits Latvijā no 2014. līdz 2018. gadam ................................................................................................................... 9 2. Licencēto zāļu lieltirgotavu skaits ................................................................................................................................................ 9 3. Reģistrēto zāļu kopējais apgrozījums pēdējos 5 gados ..............................................................................................................
    [Show full text]